Questions? We're here to help. Health advisors on staff. Call us toll-free at (866) 947-6789.

Onculyn

Sante International, Inc. - Onculyn

Regular price
$59.99
Sale price
$59.99

Info: 60 Tablets

Onculyn is a patented formula of extracts from edible plants, producing a great source of antioxidants for the maintenance of good health. The all-natural extracts in this formula are processed by a unique technique to maintain the intrinsic value of the botanicals.

Product Notes:

Please note, the nutritional supplement formerly called Oncolyn (with a middle 'o') is no longer available for sale in Canada. Onculyn is the Canadian version of this product (in 2015, regulatory issues required a name change for sale in Canada). This dietary supplement is a registered product with Health Canada; the Natural Product Number is 80033810.

Onculyn was invented and formulated by Arthur H.K. Djang, M.D., Ph.D., M.P.H. It is manufactured in Canada for Santé International, Inc. of Burnaby, BC.


Aviva Customer Review

I like to keep some Oncolyn on hand at all times. Since the first time I used it about three years ago, I haven't had a protracted cold at all. At the first signs of a virus getting hold, I begin to take some Oncolyn and all signs of illness are gone swiftly. That's in a day or so. My usual pattern was that a cold would develop into bronchitis and/or pneumonia at least once a year. Then, I'd catch another in short order and often repeat the entire illness immediately. Now, I've been looking after my health in many ways better lately than before, but I credit Oncolyn with the distinct difference in this area.

- Jan Wristen


Onculyn is an antioxidant dietary supplement. Consult your health practitioner for information on any other nutritional applications. The following research information is provided by Sante International regarding this formula, which is sold as 'Oncolyn' in the United States:

Plants are considered a valuable resource for the discovery and development of novel, naturally derived agents to treat cancer. To date, six plant-derived anticancer drugs have received FDA approval for commercial production (Taxol, vinblastine, vincristine, topotecan, etoposide, and teniposide) with others being evaluated in clinical trials worldwide, such as camptothecin. Oncolyn, a formulated combination of extracts from three edible plants, was evaluated by itself, or in combination with cytoxan/adriamycin/cisplatin, 5_FU and methotrexate, for anticancer activity in a mouse subrenal capsule assay and subsequent clinical application for various tumors.

The mouse subrenal capsule assay technique is a well accepted model in which potential antitumor agents are tested for efficacy in inhibiting growth of human tumor xenografts. The subrenal capsule assay has been used to determine anti-cancer activity of various agents against one or more human tumors including renal cell carcinoma, colorectal cancer, breast cancer, liver cancer, choriocarcinoma, ovarian adenocarcinoma, lung cancer, esophageal cancer, prostate carcinoma, and urinary bladder carcinoma. The use of the subrenal capsule human tumor xenograft assay has also been validated as a model that can accurately evaluate chemotherapeutic agents for clinical efficacy with concordance rate ranges from 77 - 90%.

The mouse subrenal capsule assay with human tumor xenografts was performed with surgically removed tumor tissues, according to the technique of Bogden and Griffin. Small tumor explant fragment circa 1mm3 size was implanted below the transparent mouse renal capsule. After abdominal wall closure, mice (105 for each experiment) were observed for the effect of Oncolyn and standard chemotherapeutic agents. On day 5, tumor fragment size, vascularity and tumor cellular changes were recorded. Oncolyn causes reduction of tumor size, inhibited vascularity on the surface and in the periphery of implanted tumor fragment and other morphological changes such as karyopyknosis and karyorrhexis consistent with apoptosis.

In summary, Oncolyn alone or in combination with other chemotherapeutic agents synergistically inhibited the growth of implanted human breast carcinoma, squamous cell carcinoma of the lung and adenocarcinoma of the rectum in mice.

Results of clinical application of Oncolyn for chemoprevention and therapy for patients with breast carcinoma, prostate carcinoma, colon carcinoma, lung carcinoma, breast intraductal papilloma, melanoma, and lymphoma will be on display. Oncolyn showed no known side effects.

Ingredients:

Each Tablet Contains 750 mg Onculyn, with:
100 mg Proanthocyanidins, 100 mg Plant Polyphenols, and 100 mg Plant Saponins.

Medicinal Ingredients:
100.0 mg Camellia sinensis (55.0% EGCG, 0.5% caffeine)
100.0 mg Crataegus laevigata (Dried Berry) (5:1 DHE: 500 mg)
100.0 mg Gynostemma pentaphyllum (5:1 DHE: 500 mg)

Non-medicinal ingredients: Croscarmellose sodium, Dicalcium Phosphate Anhydrous, Vegetable Grade Magnesium Stearate, Microcrystalline cellulose, Silicon dioxide, Stearic Acid.

Suggested Usage:

Take one Onculyn tablet twice daily or as directed by your health care practitioner.

Warnings:

Do not use if pregnant or breastfeeding. Consult a health care practitioner prior to use if you are taking heart or blood pressure medication, or if you have a liver disorder, or an iron deficiency, or if you are taking cardiac glycosides such as digitalis/digoxin, or blood pressure medication. Consult a health care practitioner if you develop symptoms of liver trouble after using.